Discovery of Gemilukast (ONO-6950), a Dual CysLT1 and CysLT2 Antagonist As a Therapeutic Agent for Asthma-Reference-Cited by-同舟云学术

Discovery of Gemilukast (ONO-6950), a Dual CysLT1 and CysLT2 Antagonist As a Therapeutic Agent for Asthma

Published:2015-07-22 Issue:15 Volume:58 Page:6093-6113
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Itadani Satoshi,Yashiro Kentaro,Aratani Yoshiyuki,Sekiguchi Tetsuya,Kinoshita Atsushi,Moriguchi Hideki,Ohta Nobukazu,Takahashi Shinya,Ishida Akiharu,Tajima Yohei,Hisaichi Katsuya,Ima Masaki,Ueda Junya,Egashira Hiromu,Sekioka Tomohiko,Kadode Michiaki,Yonetomi Yasuo,Nakao Takafumi,Inoue Atsuto,Nomura Hiroaki,Kitamine Tetsuya,Fujita Manabu,Nabe Takeshi¹²,Yamaura Yoshiyuki,Matsumura Naoya,Imagawa Akira,Nakayama Yoshisuke,Takeuchi Jun,Ohmoto Kazuyuki

Affiliation:

1. Faculty of Pharmaceutical Sciences, Setsunan University, 45-1 Nagaotoge, Hirakata, Osaka 573-0101, Japan

2. Department of Pharmacology, Kyoto Pharmaceutical University, 5 Nakauchi Misasagi, Yamashina, Kyoto 607-8414, Japan

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.5b00741

Reference43 articles.

1. Leukotrienes: Mediators of Immediate Hypersensitivity Reactions and Inflammation

2. Cysteinyl leukotriene receptors

3. Functional characteristics of cysteinyl-leukotriene receptor subtypes

4. Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: Critical update and emerging trends

5. Characterization of the human cysteinyl leukotriene CysLT1 receptor

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neuromodulatory effects of leukotriene receptor antagonists: A comprehensive review;European Journal of Pharmacology;2024-09

2. Structures of Leukotriene Biosynthetic Enzymes and Development of New Therapeutics;Annual Review of Pharmacology and Toxicology;2023-01-20

3. Montelukast and Acute Coronary Syndrome: The Endowed Drug;Pharmaceuticals;2022-09-14

4. Leukotrienes vs. Montelukast—Activity, Metabolism, and Toxicity Hints for Repurposing;Pharmaceuticals;2022-08-23

5. Building on endogenous lipid mediators to design synthetic receptor ligands;European Journal of Medicinal Chemistry;2022-03